Skip to content

Study · Animal study (in vivo) · mouse · 1987

3 results

Thymosin-alpha 1 increases the capability to produce interleukin-3 but not interleukin-2 in nu/nu mice.

Ohta Y, Tezuka E, Tamura S, Sugawara M, Nihira S, Imai S, Yagi Y

Journal of biological response modifiers1 Apr 1987Cited by 2 (Europe PMC)

PMID3495643 (opens in a new tab)PepBankPUB-03495643
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In nu/nu mice, thymosin alpha‑1 increased the capability to produce interleukin-3.

    In plain wordsIn mice without a thymus, thymosin alpha‑1 increased the ability to make interleukin-3.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseCapability to produce interleukin-3
    Study

    mousen: not reported in source

    nu/nu mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    0.5 and 5.0 µg/kg twice a week · intraperitoneal · 3-6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Thymosin-alpha 1 increased the capability of nu/nu mice to produce interleukin (IL)-3 but not IL-2 when administered intraperitoneally at doses of 0.5 and 5.0 micrograms/kg twice a week for 3-6 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In nu/nu mice, thymosin alpha‑1 did not increase the capability to produce interleukin-2, and no interleukin-2 activity was detected in any chromatography fraction.

    In plain wordsIn mice without a thymus, thymosin alpha‑1 did not increase the ability to make interleukin-2.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeCapability to produce interleukin-2
    Study

    mousen: not reported in source

    nu/nu mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    0.5 and 5.0 µg/kg twice a week · intraperitoneal · 3-6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Thymosin-alpha 1 increased the capability of nu/nu mice to produce interleukin (IL)-3 but not IL-2 when administered intraperitoneally at doses of 0.5 and 5.0 micrograms/kg twice a week for 3-6 weeks.
    1 context sentence
    Summary · context
    However, IL-2 activity determined by proliferation of the IL-2-dependent cell line was not detected in any fractions of the same chromatography.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In thymosin alpha‑1 treated nu/nu mice, Thy-1-positive cells were responsible for interleukin-3 production.

    In plain wordsIn mice without a thymus, a type of immune cell marked Thy-1 made the interleukin-3.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableCell source of interleukin-3 in treated nu/nu mice
    Study

    mousen: not reported in source

    nu/nu mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    0.5 and 5.0 µg/kg twice a week · intraperitoneal · 3-6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Thy-1-positive cells were responsible for the production of IL-3, which was determined by proliferation of the IL-3-dependent cell line (FDC-P2) as well as by augmentation of the in vitro growth of hematopoietic stem cells (colony-forming unit S [CFU-S]).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.